DK1225870T3 - Sammensætning og fremgangsmåde til cancerantigenimmunterapi - Google Patents

Sammensætning og fremgangsmåde til cancerantigenimmunterapi

Info

Publication number
DK1225870T3
DK1225870T3 DK00968692T DK00968692T DK1225870T3 DK 1225870 T3 DK1225870 T3 DK 1225870T3 DK 00968692 T DK00968692 T DK 00968692T DK 00968692 T DK00968692 T DK 00968692T DK 1225870 T3 DK1225870 T3 DK 1225870T3
Authority
DK
Denmark
Prior art keywords
patient
lymphocytes
composition
effector
cancer antigen
Prior art date
Application number
DK00968692T
Other languages
Danish (da)
English (en)
Inventor
Gary W Wood
Original Assignee
Tvax Biomedical Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tvax Biomedical Llc filed Critical Tvax Biomedical Llc
Application granted granted Critical
Publication of DK1225870T3 publication Critical patent/DK1225870T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46432—Nervous system antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/47—Brain; Nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/49—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/56—Kidney

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK00968692T 1999-10-05 2000-10-05 Sammensætning og fremgangsmåde til cancerantigenimmunterapi DK1225870T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/412,681 US6406699B1 (en) 1999-10-05 1999-10-05 Composition and method of cancer antigen immunotherapy
PCT/US2000/027399 WO2001024771A1 (fr) 1999-10-05 2000-10-05 Composition et methode d'immunotherapie antigenique anticancereuse

Publications (1)

Publication Number Publication Date
DK1225870T3 true DK1225870T3 (da) 2007-05-07

Family

ID=23634000

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00968692T DK1225870T3 (da) 1999-10-05 2000-10-05 Sammensætning og fremgangsmåde til cancerantigenimmunterapi

Country Status (11)

Country Link
US (2) US6406699B1 (fr)
EP (1) EP1225870B1 (fr)
AT (1) ATE349198T1 (fr)
AU (1) AU7856700A (fr)
CA (1) CA2388221C (fr)
CY (1) CY1106400T1 (fr)
DE (1) DE60032622T2 (fr)
DK (1) DK1225870T3 (fr)
ES (1) ES2279772T3 (fr)
PT (1) PT1225870E (fr)
WO (1) WO2001024771A1 (fr)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL143094A0 (en) * 1998-12-02 2002-04-21 Pfizer Prod Inc METHODS AND COMPOSITIONS FOR RESTORING CONFORMATIONAL STABILITY OF A PROTEIN OF THE p53 FAMILY
US7541184B2 (en) * 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
EP1368061B1 (fr) * 2000-10-20 2008-12-24 Tsuneya Ohno Cellules de fusion et compositions cytokiniques pour le traitement de maladies
US20070154399A1 (en) * 2000-10-27 2007-07-05 Hadden John W Immunotherapy for immune suppressed patients
US6977072B2 (en) 2000-10-27 2005-12-20 Irx Therapeutics, Inc. Vaccine immunotherapy for immune suppressed patients
US20070025958A1 (en) 2000-10-27 2007-02-01 Hadden John W Vaccine immunotherapy
WO2003050135A2 (fr) 2001-12-07 2003-06-19 Board Of Regents The University Of Texas System Utilisation de proteine b2l de parapox pour modifier les reponses immunes a des antigenes administres
WO2003072032A2 (fr) * 2002-02-22 2003-09-04 Intracel Resources Llc Compositions de cellules tumorales non oncogenes immunogenes steriles et methodes
AU2003225791A1 (en) * 2002-03-15 2003-09-29 Department Of Veterans Affairs, Rehabilitation R And D Service Methods and compositions for directing cells to target organs
US20050084967A1 (en) 2002-06-28 2005-04-21 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
US20040175373A1 (en) * 2002-06-28 2004-09-09 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
US20040151704A1 (en) * 2002-06-28 2004-08-05 Xcyte Therapies, Inc. Compositions and methods for restoring immune repertoire in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
MXPA05008936A (es) * 2003-02-21 2006-05-25 Univ Maryland Adyuvante para vacunas con linfocitos humanos.
MX2010005718A (es) 2007-11-28 2010-08-10 Irx Therapeutics Inc Metodo para incrementar el efecto inmunologico.
CA2754109A1 (fr) * 2009-03-09 2010-09-16 Tvax Biomedical, Llc Immunotherapie cellulaire de maladie infectieuse
EP2429585B1 (fr) 2009-05-15 2018-04-18 IRX Therapeutics, Inc. Immunothérapie par vaccin
AU2010328197B2 (en) 2009-12-08 2015-07-16 Irx Therapeutics, Inc. Method of reversing immune suppression of Langerhans cells
US10426740B1 (en) 2010-08-18 2019-10-01 Avm Biotechnology, Llc Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues
ES2771251T3 (es) 2013-03-01 2020-07-06 Us Health Métodos de producción de poblaciones enriquecidas de células T reactivas con tumores a partir de sangre periférica
SI3302507T1 (sl) 2015-05-28 2023-10-30 The United States of America, as represented by The Secretary, Department of Health and Human Services, Diagnostični postopki za t celično terapijo
KR20230147769A (ko) 2015-05-28 2023-10-23 카이트 파마 인코포레이티드 T 세포 요법을 위해 환자를 컨디셔닝하는 방법
JP2018526428A (ja) * 2015-09-09 2018-09-13 ティーブイエーエックス バイオメディカル アイ，リミティド ライアビリティ カンパニー 養子ｔ細胞療法と腫瘍溶解性ウイルス補助療法とを組み合わせる方法
IL305306A (en) 2015-10-20 2023-10-01 Us Health Methods of preparing T cells for T cell therapy
US11781112B2 (en) * 2016-03-06 2023-10-10 Kareem Thomas Robinson Method of generating antigen-specific immunological memory in a subject that rejects classical vaccines
MX2018012017A (es) 2016-04-01 2019-07-04 Kite Pharma Inc Antigeno quimerico y receptores de celulas t y metodos de uso.
NZ746700A (en) 2016-04-01 2023-04-28 Kite Pharma Inc Bcma binding molecules and methods of use thereof
CA3019650C (fr) 2016-04-01 2023-07-25 Kite Pharma, Inc. Recepteurs chimeriques et leurs procedes d'utilisation
WO2018106958A1 (fr) * 2016-12-07 2018-06-14 Transtarget, Inc. Procédés et compositions pour vacciner et fortifier des patients atteints d'un cancer
ES2900233T3 (es) 2017-02-14 2022-03-16 Kite Pharma Inc Moléculas que se unen a CD70 y métodos de uso de las mismas
WO2018169922A2 (fr) 2017-03-13 2018-09-20 Kite Pharma, Inc. Récepteurs antigéniques chimériques pour le mélanome et leurs utilisations
MX2019011679A (es) 2017-04-01 2019-11-01 Avm Biotechnology Llc Reemplazo de un pre-acondicionamiento citotoxico antes de una inmunoterapia celular.
AR111360A1 (es) 2017-04-03 2019-07-03 Kite Pharma Inc Tratamiento usando células t de receptor quimérico incorporando células t polifuncionales optimizadas
JOP20180042A1 (ar) 2017-04-24 2019-01-30 Kite Pharma Inc نطاقات ربط مولد ضد متوافقة مع البشر وطرق الاستخدام
CN110662831A (zh) 2017-05-26 2020-01-07 凯德药业股份有限公司 制备和使用胚胎间充质祖细胞的方法
KR102521245B1 (ko) * 2017-09-15 2023-04-17 카이트 파마 인코포레이티드 관리 연속성 및 신원 연속성 생물학적 샘플 추적으로 환자-특이적 면역요법 절차를 수행하기 위한 방법 및 시스템
SG11202002533QA (en) 2017-09-22 2020-04-29 Kite Pharma Inc Chimeric polypeptides and uses thereof
US20190151361A1 (en) 2017-10-18 2019-05-23 Kite Pharma, Inc. Methods of administering chimeric antigen receptor immunotherapy
WO2019099707A1 (fr) 2017-11-16 2019-05-23 Kite Pharma, Inc Récepteurs antigéniques chimériques modifiés et procédés d'utilisation
CA3087481A1 (fr) 2018-01-15 2019-07-18 Pfizer Inc. Methodes d'administration d'immunotherapie par recepteur d'antigene chimerique en combinaison avec un agoniste de 4-1bb
WO2019152957A1 (fr) 2018-02-02 2019-08-08 Arizona Board Of Regents On Behalf Of Arizona State University Lymphocytes t de type adn-récepteur antigénique chimérique pour immunothérapie
SG11202007513PA (en) 2018-02-16 2020-09-29 Kite Pharma Inc Modified pluripotent stem cells and methods of making and use
IL310416A (en) 2018-04-12 2024-03-01 Kite Pharma Inc Chimeric T cell receptor therapy using tumor microenvironmental characteristics
TW202003021A (zh) 2018-06-01 2020-01-16 美商凱特製藥公司 嵌合抗原受體t細胞療法
EP3810780A1 (fr) 2018-06-22 2021-04-28 Kite Pharma Eu B.V. Compositions et procédés pour produire des lymphocytes t modifiés
KR20210038922A (ko) 2018-08-02 2021-04-08 카이트 파마 인코포레이티드 키메라 항원 수용체 요법 t 세포 확장 동역학 및 그의 용도
EP3488851A1 (fr) 2018-10-03 2019-05-29 AVM Biotechnology, LLC Thérapies immunoablatives
EP3632446B3 (fr) 2018-10-03 2024-01-24 AVM Biotechnology, LLC Thérapies immunoablatives
US20220128562A1 (en) * 2018-11-26 2022-04-28 Dana-Farber Cancer Institute, Inc. Biomarkers predictive of cancer cell response to ml329 or a derivative thereof
WO2020113098A1 (fr) 2018-11-29 2020-06-04 Vineti Inc. Plateforme de médecine individualisée centralisée et décentralisée
WO2020123691A2 (fr) 2018-12-12 2020-06-18 Kite Pharma, Inc Récepteurs antigéniques chimériques et récepteurs de lymphocytes t et méthodes d'utilisation
US11321652B1 (en) 2019-02-20 2022-05-03 Vineti Inc. Smart label devices, systems, and methods
TW202108150A (zh) 2019-05-03 2021-03-01 美商凱特製藥公司 投與嵌合抗原受體免疫療法之方法
WO2020257823A2 (fr) 2019-06-21 2020-12-24 Kite Pharma, Inc. RÉCEPTEURS DE TGF-β ET LEURS MÉTHODES D'UTILISATION
US20210062150A1 (en) 2019-09-03 2021-03-04 Allogene Therapeutics, Inc. Methods of preparing t cells for t cell therapy
US20230293530A1 (en) 2020-06-24 2023-09-21 Yeda Research And Development Co. Ltd. Agents for sensitizing solid tumors to treatment
WO2022036041A1 (fr) 2020-08-14 2022-02-17 Kite Pharma, Inc Amélioration de la fonction de cellules immunitaires
EP4204545A2 (fr) 2020-08-25 2023-07-05 Kite Pharma, Inc. Lymphocytes t à fonctionnalité améliorée
US20220155299A1 (en) 2020-10-28 2022-05-19 Kite Pharma, Inc. Flow cytometric method for characterization of t-cell impurities
US20220204930A1 (en) 2020-12-24 2022-06-30 Kite Pharma, Inc. Prostate cancer chimeric antigen receptors
JP2024502599A (ja) 2021-01-10 2024-01-22 カイト ファーマ インコーポレイテッド Ｔ細胞療法
JP2024507199A (ja) 2021-02-20 2024-02-16 カイト ファーマ インコーポレイテッド 免疫療法を選択するための遺伝子マーカー
JP2024510162A (ja) 2021-03-11 2024-03-06 カイト ファーマ インコーポレイテッド 免疫細胞機能の改善
WO2022221028A1 (fr) 2021-04-16 2022-10-20 Kite Pharma, Inc. Molécules à liaison double taci/bcma
WO2022221126A1 (fr) 2021-04-16 2022-10-20 Kite Pharma, Inc. Procédés et systèmes de planification d'une procédure d'immunothérapie spécifique à un patient
AU2022274608A1 (en) 2021-05-14 2023-11-09 Kite Pharma, Inc. Chimeric antigen receptor t cell therapy
CN117677633A (zh) 2021-05-24 2024-03-08 凯德药业股份有限公司 基于nkg2d的嵌合抗原受体
AU2022291365A1 (en) 2021-06-08 2024-01-18 Kite Pharma, Inc. Gpc3 binding molecules
EP4363558A1 (fr) 2021-07-01 2024-05-08 Kite Pharma, Inc. Système fermé et procédé de fabrication de thérapie cellulaire autologue et allogène
EP4364151A1 (fr) 2021-07-02 2024-05-08 Kite Pharma, Inc. Procédé d'identification de variants de produits géniques à partir de constructions géniques utilisées dans des applications de thérapie cellulaire
US20230060292A1 (en) 2021-07-26 2023-03-02 Kite Pharma, Inc. Split chimeric antigen receptors and methods of use
CA3225306A1 (fr) 2021-07-30 2023-02-02 Kite Pharma, Inc. Surveillance et gestion de toxicites induites par une therapie cellulaire
US11615874B1 (en) 2021-09-30 2023-03-28 Vineti Inc. Personalized medicine and therapies platform
IL311981A (en) 2021-10-18 2024-06-01 Kite Pharma Inc Signaling domains for chimeric antigen receptors
WO2023159001A1 (fr) 2022-02-15 2023-08-24 Kite Pharma, Inc. Prédiction d'événements indésirables à partir d'une immunothérapie
US20240091261A1 (en) 2022-08-26 2024-03-21 Kite Pharma, Inc. Immune cell function
US20240158869A1 (en) 2022-10-28 2024-05-16 Kite Pharma, Inc. Factors for optimizing immunotherapy
WO2024092152A1 (fr) 2022-10-28 2024-05-02 Kite Pharma, Inc. Amélioration de l'efficacité et de la réponse durable de l'immunothérapie

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766920A (en) 1982-08-11 1998-06-16 Cellcor, Inc. Ex vivo activation of immune cells
US4828991A (en) 1984-01-31 1989-05-09 Akzo N.V. Tumor specific monoclonal antibodies
WO1988000970A2 (fr) 1986-08-08 1988-02-11 Regents Of The University Of Minnesota Procede de culture de leucocytes
US5126132A (en) 1989-08-21 1992-06-30 The United States Of America As Represented By The Department Of Health And Human Services Tumor infiltrating lymphocytes as a treatment modality for human cancer
US5728388A (en) 1989-10-03 1998-03-17 Terman; David S. Method of cancer treatment
US5290551A (en) 1990-05-08 1994-03-01 Thomas Jefferson University Treatment of melanoma with a vaccine comprising irradiated autologous melanoma tumor cells conjugated to a hapten
US5725855A (en) 1991-04-05 1998-03-10 The United States Of America As Represented By The Department Of Health And Human Services Method of treating tumors with CD8+ -depleted or CD4+ T cell subpopulations
US5637483A (en) 1991-10-04 1997-06-10 Whitehead Institute For Biomedical Research Irradiated tumor cell vaccine engineered to express GM-CSF
WO1994001133A1 (fr) 1992-07-08 1994-01-20 Schering Corporation Utilisation de facteur de stimulation de colonie de granulocytes-macrophages (fsc-gm) comme adjuvant de vaccin
US5650156A (en) * 1993-02-22 1997-07-22 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of nutriceuticals and compositions useful therefor
EP0852618A1 (fr) * 1995-07-25 1998-07-15 Celltherapy Inc. Immunotherapie par cellules autologues: compositions cellulaires , methodes et application au traitement d'une maladie humaine

Also Published As

Publication number Publication date
ATE349198T1 (de) 2007-01-15
EP1225870A1 (fr) 2002-07-31
CA2388221C (fr) 2007-12-04
EP1225870A4 (fr) 2003-05-28
US20020006409A1 (en) 2002-01-17
AU7856700A (en) 2001-05-10
US6406699B1 (en) 2002-06-18
PT1225870E (pt) 2007-06-11
DE60032622D1 (de) 2007-02-08
CY1106400T1 (el) 2011-10-12
ES2279772T3 (es) 2007-09-01
CA2388221A1 (fr) 2001-04-12
EP1225870B1 (fr) 2006-12-27
DE60032622T2 (de) 2007-12-20
WO2001024771A1 (fr) 2001-04-12

Similar Documents

Publication Publication Date Title
DK1225870T3 (da) Sammensætning og fremgangsmåde til cancerantigenimmunterapi
WO2002034205A3 (fr) Utilisation des proteines du stress pour stimuler la reponse immunitaire
HK1024268A1 (en) Method for activating human antigen presenting cells, activated human antigen presenting cells, and use of the same.
ES2113980T3 (es) Ligandos solubles para cd40.
NO20015073L (no) Vaksiner
SG46445A1 (en) Vaccines against cancer and infectious diseases
ATE389712T1 (de) Krebs immuntherapie mit semi-allogenen zellen
EP0719150A4 (fr) Vaccin cellulaire et procedes d'utilisation dans le traitement de tumeurs malignes solides
BR9811037A (pt) Utilização de ligantes mhc classe ii como coadjuvante para vacinação e de lag-3 no tratamento do câncer
US7402317B2 (en) Anti-cancer vaccine
NO981530D0 (no) Pasientspesifikke immunoadsorpsjonsmidler for utenomkroppslig aferese og fremgangsmåter for fremstilling av immunoadsorpsjonsmidlene
WO2003090687A3 (fr) Utilisation de proteines de choc thermique pour renforcer la reponse immunitaire
DE60128070D1 (de) Impfstoff spezifisch gegen nierentumore, gerichtet gegen das antigen g-250 des nierentumors
NZ507829A (en) Vaccine adjuvants for immunotherapy of melanoma
MXPA03005030A (es) Juego de reactivos inmunoterapeuticos para el tratamiento de tumores.
Takigawa et al. Percutaneous Peptide Immunization via Corneum Barrier‐disrupted Murine Skin for Experimental Tumor Immunoprophylaxis
WO2005009397A3 (fr) Adjuvant de vaccin à base de lymphocytes humains
NO930798L (no) Fremgangsmaate og middel mot tumorer
RU2000122041A (ru) Способ лечения злокачественных опухолей головного мозга
MY127452A (en) Vaccines.
MX9604099A (es) Inmunoterapia de cancer con linfocitos alogenicos.
RU2000111634A (ru) Способ комбинированной иммунотерапии злокачественных опухолей головного мозга
Prescott New therapeutic approaches for treating lymphomas
UA49704A (uk) Спосіб ендоскопічного лікування раннього раку шлунку і великого сосочка дванадцятипалої кишки за в.с. довбенком і о.в. довбенком
UA38574A (uk) Спосіб лікування злоякісної пухлини